HC Wainwright & Co. Reiterates Buy on Arrowhead Pharma, Maintains $80 Price Target

Benzinga · 09/02/2025 16:05
HC Wainwright & Co. analyst Patrick R. Trucchio reiterates Arrowhead Pharma (NASDAQ:ARWR) with a Buy and maintains $80 price target.